-
2
-
-
0022978869
-
In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline
-
R.G. Goldie, D. Spina, P.J. Henry, K.M. Lulich, and J.W. Paterson In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline Br. J. Clin. Pharmacol. 22 1986 669 676
-
(1986)
Br. J. Clin. Pharmacol.
, vol.22
, pp. 669-676
-
-
Goldie, R.G.1
Spina, D.2
Henry, P.J.3
Lulich, K.M.4
Paterson, J.W.5
-
3
-
-
34447120838
-
Reducing cholinergic constriction: The major reversible mechanism in COPD
-
V. Brusasco Reducing cholinergic constriction: the major reversible mechanism in COPD Eur. Respir. Rev. 15 2006 32 36
-
(2006)
Eur. Respir. Rev.
, vol.15
, pp. 32-36
-
-
Brusasco, V.1
-
6
-
-
84867119092
-
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study
-
P.W. Jones, D. Singh, E.D. Bateman, A. Agusti, R. Lamarca, G. de Miquel, and et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study Eur. Respir. J. 40 2012 830 836
-
(2012)
Eur. Respir. J.
, vol.40
, pp. 830-836
-
-
Jones, P.W.1
Singh, D.2
Bateman, E.D.3
Agusti, A.4
Lamarca, R.5
De Miquel, G.6
-
7
-
-
84859305834
-
Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)
-
E.M. Kerwin, A.D. D'Urzo, A.F. Gelb, H. Lakkis, E. Garcia Gil, C.F. Caracta, and et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I) COPD 9 2012 90 101
-
(2012)
COPD
, vol.9
, pp. 90-101
-
-
Kerwin, E.M.1
D'Urzo, A.D.2
Gelb, A.F.3
Lakkis, H.4
Garcia Gil, E.5
Caracta, C.F.6
-
8
-
-
84890299585
-
ACCORD COPD II: A randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients
-
S.I. Rennard, P.D. Scanlon, G.T. Ferguson, L. Rekeda, B.T. Maurer, E. Garcia Gil, and et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients Clin. Drug Investig. 33 2013 893 904
-
(2013)
Clin. Drug Investig.
, vol.33
, pp. 893-904
-
-
Rennard, S.I.1
Scanlon, P.D.2
Ferguson, G.T.3
Rekeda, L.4
Maurer, B.T.5
Garcia Gil, E.6
-
9
-
-
37349061064
-
Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease
-
W.E. Berger, and J.A. Nadel Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease Respir. Med. 102 2008 173 188
-
(2008)
Respir. Med.
, vol.102
, pp. 173-188
-
-
Berger, W.E.1
Nadel, J.A.2
-
12
-
-
84965085606
-
Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: The 24-week, randomized, placebo-controlled AUGMENT COPD study
-
A.D. D'Urzo, S.I. Rennard, E.M. Kerwin, V. Mergel, A.R. Leselbaum, and C.F. Caracta Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study Respir. Res. 15 2014 123 141
-
(2014)
Respir. Res.
, vol.15
, pp. 123-141
-
-
D'Urzo, A.D.1
Rennard, S.I.2
Kerwin, E.M.3
Mergel, V.4
Leselbaum, A.R.5
Caracta, C.F.6
-
13
-
-
84921459850
-
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): A multicentre, randomised study
-
D. Singh, P.W. Jones, E.D. Bateman, S. Korn, C. Serra, E. Molins, and et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study BMC Pulm. Med. 14 2014 178 189
-
(2014)
BMC Pulm. Med.
, vol.14
, pp. 178-189
-
-
Singh, D.1
Jones, P.W.2
Bateman, E.D.3
Korn, S.4
Serra, C.5
Molins, E.6
-
15
-
-
84926500092
-
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)
-
R. Buhl, F. Maltais, R. Abrahams, L. Bjermer, E. Derom, G. Ferguson, and et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4) Eur. Respir. J. 45 2015 969 979
-
(2015)
Eur. Respir. J.
, vol.45
, pp. 969-979
-
-
Buhl, R.1
Maltais, F.2
Abrahams, R.3
Bjermer, L.4
Derom, E.5
Ferguson, G.6
-
16
-
-
84904081919
-
Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: Results from a 52-week, randomized, double-blind, placebo-controlled study
-
J.F. Donohue, D. Niewoehner, J. Brooks, D. O'Dell, and A. Church Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study Respir. Res. 15 2014 78 88
-
(2014)
Respir. Res.
, vol.15
, pp. 78-88
-
-
Donohue, J.F.1
Niewoehner, D.2
Brooks, J.3
O'Dell, D.4
Church, A.5
-
17
-
-
77956338422
-
A one-year trial of tiotropium Respimat plus usual therapy in COPD patients
-
E.D. Bateman, D. Tashkin, N. Siafakas, R. Dahl, L. Towse, D. Massey, and et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients Respir. Med. 104 2010 1460 1472
-
(2010)
Respir. Med.
, vol.104
, pp. 1460-1472
-
-
Bateman, E.D.1
Tashkin, D.2
Siafakas, N.3
Dahl, R.4
Towse, L.5
Massey, D.6
-
18
-
-
84868554172
-
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: The GLOW2 study
-
E. Kerwin, J. Hébert, N. Gallagher, C. Martin, T. Overend, V.K. Alagappan, and et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Eur. Respir. J. 40 2012 1106 1114
-
(2012)
Eur. Respir. J.
, vol.40
, pp. 1106-1114
-
-
Kerwin, E.1
Hébert, J.2
Gallagher, N.3
Martin, C.4
Overend, T.5
Alagappan, V.K.6
-
19
-
-
84896711038
-
Once daily glycopyrronium for the treatment of COPD: Pooled analysis of the GLOW1 and GLOW2 studies
-
A. D'Urzo, E. Kerwin, T. Overend, P. D'Andrea, H. Chen, and P. Goyal Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies Curr. Med. Res. Opin. 30 2014 493 508
-
(2014)
Curr. Med. Res. Opin.
, vol.30
, pp. 493-508
-
-
D'Urzo, A.1
Kerwin, E.2
Overend, T.3
D'Andrea, P.4
Chen, H.5
Goyal, P.6
-
20
-
-
80052967109
-
Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients
-
D.P. Tashkin, S. Rennard, H.J. Taylor, D. Lawrence, J.P. Marton, and T.C. Lee Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients Respir. Med. 105 2011 1682 1690
-
(2011)
Respir. Med.
, vol.105
, pp. 1682-1690
-
-
Tashkin, D.P.1
Rennard, S.2
Taylor, H.J.3
Lawrence, D.4
Marton, J.P.5
Lee, T.C.6
-
21
-
-
84893596103
-
Minimal clinically important differences in pharmacological trials
-
P.W. Jones, K.M. Beeh, K.R. Chapman, M. Decramer, D.A. Mahler, and J.A. Wedzicha Minimal clinically important differences in pharmacological trials Am. J. Respir. Crit. Care Med. 189 2014 250 255
-
(2014)
Am. J. Respir. Crit. Care Med.
, vol.189
, pp. 250-255
-
-
Jones, P.W.1
Beeh, K.M.2
Chapman, K.R.3
Decramer, M.4
Mahler, D.A.5
Wedzicha, J.A.6
-
22
-
-
84930615525
-
Pharmacological interaction between LABAs and LAMAs in the airways: Optimizing synergy
-
L. Calzetta, M.G. Matera, and M. Cazzola Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy Eur. J. Pharmacol. 761 2015 168 173
-
(2015)
Eur. J. Pharmacol.
, vol.761
, pp. 168-173
-
-
Calzetta, L.1
Matera, M.G.2
Cazzola, M.3
-
23
-
-
26944440146
-
Distribution of receptor targets in the lung
-
P.J. Barnes Distribution of receptor targets in the lung Proc. Am. Thorac. Soc. 1 2004 345 351
-
(2004)
Proc. Am. Thorac. Soc.
, vol.1
, pp. 345-351
-
-
Barnes, P.J.1
-
24
-
-
84968662845
-
Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies
-
September
-
S. Korn, E. Kerwin, J.F. Donohue, P. Shrestha, A. Leselbaum, and A. Lei Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: pooled analyses of three phase III studies Poster Presented at the European Respiratory Society, Munich, Germany, 6-10 September 2014
-
(2014)
Poster Presented at the European Respiratory Society, Munich, Germany, 6-10
-
-
Korn, S.1
Kerwin, E.2
Donohue, J.F.3
Shrestha, P.4
Leselbaum, A.5
Lei, A.6
|